Search
Pyxis Oncology Inc
PYXSAdd to Watchlist
2.650USD
-0.220-7.67%
Close 07-31 16:00（ET）Quotes delayed by 15 min
219.83MMarket Cap
LossP/E TTM
More Details of Pyxis Oncology Inc Company
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Pyxis Oncology Inc Info
Ticker SymbolPYXS
Company namePyxis Oncology Inc
IPO dateOct 08, 2021
CEOSullivan (Lara S)
Number of employees44
Security typeOrdinary Share
Fiscal year-endOct 08
Address321 Harrison Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02118
Phone16172219059
Websitehttps://pyxisoncology.com/
Ticker SymbolPYXS
IPO dateOct 08, 2021
CEOSullivan (Lara S)
Company Executives of Pyxis Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
321.38K
-56.48%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
--
Dr. Freda C. Lewis-Hall, M.D.
Dr. Freda C. Lewis-Hall, M.D.
Independent Director
Independent Director
241.41K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
--
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Lara S. Sullivan, M.D.
Dr. Lara S. Sullivan, M.D.
Director, President, Chief Executive Officer and Chief Medical Officer
Director, President, Chief Executive Officer and Chief Medical Officer
--
--
Mr. John L. Flavin
Mr. John L. Flavin
Independent Chairman Of The Board
Independent Chairman Of The Board
--
--
Dr. Rachel W. Humphrey, M.D.
Dr. Rachel W. Humphrey, M.D.
Independent Director
Independent Director
--
--
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
321.38K
-56.48%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
--
Dr. Freda C. Lewis-Hall, M.D.
Dr. Freda C. Lewis-Hall, M.D.
Independent Director
Independent Director
241.41K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
--
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
FAQs
Who are the top five shareholders of Pyxis Oncology Inc?
The top five shareholders of Pyxis Oncology Inc are: Mr. Jitendra Wadhane
How many institutions hold shares of Pyxis Oncology Inc (PYXS)?
As of 2026Q1, 221 institutions hold shares of Pyxis Oncology Inc, with a combined market value of approximately 25.75M, accounting for 40.97% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -13574955.00.